In vivo evaluation of efficacy and safety of Coagulansin-A in treating arthritis

IF 3.3 3区医学 Q2 PHARMACOLOGY & PHARMACY Toxicology and applied pharmacology Pub Date : 2024-06-20 DOI:10.1016/j.taap.2024.117008

Sadaf Naz , Muhammad Usama Mazhar , Sidra Faiz , Maria Nawaz Malik , Jehan Zeb Khan , Ihsan Ul Haq , Lin Zhu , Muhammad Khalid Tipu

{"title":"In vivo evaluation of efficacy and safety of Coagulansin-A in treating arthritis","authors":"Sadaf Naz , Muhammad Usama Mazhar , Sidra Faiz , Maria Nawaz Malik , Jehan Zeb Khan , Ihsan Ul Haq , Lin Zhu , Muhammad Khalid Tipu","doi":"10.1016/j.taap.2024.117008","DOIUrl":null,"url":null,"abstract":"<div><p>The current study aimed to determine the safety and efficacy of Coag-A through in vivo analysis in CFA induced mice model. Treatment of CFA induced arthritis in mice with Coagulansin-A (10 mg/kg i.p. daily for 28 days), a withanolide obtained from <em>Withania coagulans,</em> as well as standard drug treatment with Dexamethasone (5 mg/kg i.p) was provided. The effect of Coag-A on body weight, relative organ weight, hematology, serum biochemistry, survival rate, oxidative stress markers, and antioxidant enzymes was evaluated. The liver and kidney histopathology were also assessed to ascertain its safety profile. Treatment of arthritic mice with Coag-A considerably improved body weight, relative organ weight of liver, kidney, and spleen, ameliorated hematology and serum biochemistry, and increased survival and antioxidant potential. Coag-A was found to be safer with fewer adverse effects showing hepato-protective, nephroprotective, and anti-inflammatory effect. It also significantly (<em>p</em> < 0.001) improved histopathology of CFA-induced mice when compared with Dexa. In conclusion, compared to dexamethasone, Coag-A has demonstrated a greater therapeutic benefit and fewer side effects in the treatment of arthritis against the CFA-induced model.</p></div>","PeriodicalId":23174,"journal":{"name":"Toxicology and applied pharmacology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicology and applied pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041008X24002060","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The current study aimed to determine the safety and efficacy of Coag-A through in vivo analysis in CFA induced mice model. Treatment of CFA induced arthritis in mice with Coagulansin-A (10 mg/kg i.p. daily for 28 days), a withanolide obtained from Withania coagulans, as well as standard drug treatment with Dexamethasone (5 mg/kg i.p) was provided. The effect of Coag-A on body weight, relative organ weight, hematology, serum biochemistry, survival rate, oxidative stress markers, and antioxidant enzymes was evaluated. The liver and kidney histopathology were also assessed to ascertain its safety profile. Treatment of arthritic mice with Coag-A considerably improved body weight, relative organ weight of liver, kidney, and spleen, ameliorated hematology and serum biochemistry, and increased survival and antioxidant potential. Coag-A was found to be safer with fewer adverse effects showing hepato-protective, nephroprotective, and anti-inflammatory effect. It also significantly (p < 0.001) improved histopathology of CFA-induced mice when compared with Dexa. In conclusion, compared to dexamethasone, Coag-A has demonstrated a greater therapeutic benefit and fewer side effects in the treatment of arthritis against the CFA-induced model.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

体内评估凝固素 A 治疗关节炎的有效性和安全性。

本研究旨在通过对 CFA 诱导的小鼠模型进行体内分析，确定凝集素-A 的安全性和有效性。研究人员用凝血活酶-A（一种从睡莲科植物薇甘菊中提取的山奈酚内酯，每天 10 毫克/千克，静脉注射，连续 28 天）治疗 CFA 诱导的小鼠关节炎，并用地塞米松（5 毫克/千克，静脉注射）进行标准药物治疗。评估了凝血活酶 A 对体重、相对器官重量、血液学、血清生化学、存活率、氧化应激标记物和抗氧化酶的影响。此外，还对肝脏和肾脏组织病理学进行了评估，以确定其安全性。用 Coag-A 治疗关节炎小鼠可显著改善体重、肝脏、肾脏和脾脏的相对器官重量，改善血液学和血清生化指标，提高存活率和抗氧化潜力。研究发现，Coag-A 更安全，不良反应更少，具有保护肝脏、保护肾脏和抗炎作用。它还能明显（p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Toxicology and applied pharmacology 医学-毒理学

CiteScore

6.80

自引率

2.60%

发文量

309

审稿时长

32 days

期刊介绍： Toxicology and Applied Pharmacology publishes original scientific research of relevance to animals or humans pertaining to the action of chemicals, drugs, or chemically-defined natural products. Regular articles address mechanistic approaches to physiological, pharmacologic, biochemical, cellular, or molecular understanding of toxicologic/pathologic lesions and to methods used to describe these responses. Safety Science articles address outstanding state-of-the-art preclinical and human translational characterization of drug and chemical safety employing cutting-edge science. Highly significant Regulatory Safety Science articles will also be considered in this category. Papers concerned with alternatives to the use of experimental animals are encouraged. Short articles report on high impact studies of broad interest to readers of TAAP that would benefit from rapid publication. These articles should contain no more than a combined total of four figures and tables. Authors should include in their cover letter the justification for consideration of their manuscript as a short article.